You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Phase II trials: SVR Rate with DAA in HCVG 2-3 naives and experienced (NOT HEAD TO HEAD STUDIES)

From: Top topics in HCV research arena

DAA Class DAA Duration PR Duration N SVR 4*/24 Naives SVR 4 experienced
PR+GS-7977 NS5bPolI 12 wk 12 wk 12 wk 12 wk 8 wk 4 wk 11 10 9 11/11 10/10 10/10  
GS-7977 + R Ns5bPolI 12 wk 0 11 11/11  
GS-7977+ R Ns5bPolI 12 wk 0 25   12/15
GS7977 + Daclatasvir + R NNS5bPolI + NS5aPolI + R 24 wk 24 wk 0 0 30 14 28/30* 11/14*  
  1. Abbreviations: DAA: Directly Acting Antiviral; NS5b PolI : NS5b polymerase inhibitor; NS5a Polymerase Inhibitor; PR Pegylated Interferon combined with Ribavirin; wk: week; SVR: Sustained Virologic Response; SVR 4: HCVRNA below the level of detection with Roche TaqMan assay 4 weeks after treatment withdrawal; SVR 24: HCVRNA below the level of detection with Roche TaqMan assay 24 weeks after treatment withdrawal